Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies ; volume:10 ; number:1 ; day:29 ; month:3 ; year:2019 ; pages:1-10 ; date:12.2019
Nature Communications ; 10, Heft 1 (29.3.2019), 1-10, 12.2019
- Classification
-
Naturwissenschaften
- Creator
-
Hobson, James J.
Al-khouja, Amer
Curley, Paul
Meyers, David
Flexner, Charles
Siccardi, Marco
Owen, Andrew
Meyers, Caren Freel
Rannard, Steve P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-019-09354-z
- URN
-
urn:nbn:de:101:1-2019041621080044346146
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hobson, James J.
- Al-khouja, Amer
- Curley, Paul
- Meyers, David
- Flexner, Charles
- Siccardi, Marco
- Owen, Andrew
- Meyers, Caren Freel
- Rannard, Steve P.
- SpringerLink (Online service)
Other Objects (12)
Long-Acting Reversible Contraception
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Parenteral platforms for tunable, long-acting administration of a highly hydrophobic antiretroviral drug
Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy
Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
Development of long-acting ARV’s
Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy
Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda
Creation of a long-acting nanoformulated dolutegravir
Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya
Long-Acting Reversible Contraception
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Parenteral platforms for tunable, long-acting administration of a highly hydrophobic antiretroviral drug
Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy
Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
Development of long-acting ARV’s
Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy
Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda
Creation of a long-acting nanoformulated dolutegravir
Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya
Long-Acting Reversible Contraception
Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?
Parenteral platforms for tunable, long-acting administration of a highly hydrophobic antiretroviral drug
Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy
Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
Development of long-acting ARV’s
Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy
Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda
Creation of a long-acting nanoformulated dolutegravir
Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages